D. Western Therapeutics Institute, Inc. 2Q Earnings Preview

A pivotal quarter centering on K-321 data readout and Bondlido US launch progress, with attention also on the timing of TissueBlue contract extension revenue recognition

PublishedAugust 10, 2026 at 15:30 GMT+9

Summary

Heading into the 2Q results, the focus is on clinical data readouts and monetization progress—the core drivers of enterprise value—as multiple development pipelines simultaneously reach milestones. Notably, the K-321 global Phase III clinical trial has completed its full observation period and transitioned to the data analysis phase; depending on the outcome, there is significant potential to boost future earnings. Additionally, the US sales license agreement for Bondlido is expected to be signed in August, enhancing visibility into revenue streams associated with the US launch. 1Q revenue came in at just 5.0% of the full-year guidance due to the non-recognition of TissueBlue royalties, but a lump-sum catch-up booking upon contract extension agreement could lift revenue from 2Q onward—this should be evaluated separately from the optically low achievement rate. The acceleration of H-1337 development in Japan, underpinned by the capital alliance with Senju Pharmaceutical, is also a critical factor for medium- to long-term enterprise value.

Key Points for Next Quarter

Key Points & Focus	Implications
Revenue RecoveryTissueBlue royalty contract extension agreement and recognition timing	Royalties were not recognized in 1Q as contract extension negotiations with DORC were ongoing. If agreement and lump-sum catch-up recognition occur in 2Q, progress against the full-year guidance of JPY 300M could improve sharply
Pipeline ProgressK-321 global Phase III clinical trial data readout	Full observation period completed; data analysis underway. Positive results would crystallize the path to regulatory submission and trigger a re-rating of equity value
New Revenue StreamBondlido US sales license agreement execution and launch schedule	Agreement expected in August with 4Q launch. Disclosed sales volume projections exceed initial estimates, making the scale of profit-sharing payments a key focus
Liquidity / DilutionTrend in cash and deposits and potential additional fundraising	Cash of JPY 1,539M at 1Q-end plus ~JPY 195M capital injection from Senju Pharmaceutical. Need to confirm adequacy of liquidity against a quarterly cash burn rate of ~JPY 170M
Strategic PartnershipConcrete timeline following strategic pivot to Japan-first development of H-1337	Whether a Phase III trial start date in Japan is indicated under the option agreement with Senju Pharmaceutical. Development speed in the context of the competitive ophthalmology landscape will be a key determinant of enterprise value
R&D Cost ControlQuarterly trend in SG&A and R&D expenses	1Q R&D expenses of JPY 117M (−17.5% YoY) reflected a compression trend. With the launch of H-1337 Japan development, the magnitude of cost increases from 2Q onward needs to be monitored

Key Issues from Previous Results (FY12/2026 1Q)

1Q results showed revenue of JPY 15M, down −84.4% YoY due to temporary non-recognition of TissueBlue royalties, while SG&A was reduced by −20.2%, limiting the operating loss to −JPY 167M. On the development front, this was a quarter in which foundations were laid for pipeline value crystallization: the K-321 Phase III observation period was completed, an option agreement with Senju Pharmaceutical for H-1337 was executed, and a strategic pivot to Japan-first development was initiated.

1. TissueBlue Royalty Contract Extension Negotiations and Revenue Recovery

Prior Quarter:
1Q revenue of JPY 15M included zero TissueBlue royalties. Contract extension for patent-active territories has been agreed in principle with DORC, but was not booked as detailed terms remained under negotiation
This Quarter Focus:
Whether formal agreement on the contract extension is reached and whether retroactive royalties are recognized on a lump-sum basis. The key question is the extent to which TissueBlue revenue is embedded in the full-year revenue guidance of JPY 300M
Key Metrics:
2Q cumulative revenue guidance achievement rate (vs. prior-year 2Q cumulative levels), disclosed royalty amounts

2. K-321 (Fuchs Endothelial Corneal Dystrophy) Phase III Trial Data Readout

Prior Quarter:
The observation period for the remaining one of two global Phase III trials concluded in March. All trial observation periods are now complete, transitioning to data analysis
This Quarter Focus:
Timing of top-line data release and achievement of primary endpoints, along with regulatory submission timeline
Key Metrics:
Statistical significance of primary endpoints, specificity of regulatory submission schedule

3. H-1337 (Glaucoma Treatment) Japan Development Infrastructure Build-Out

Prior Quarter:
In March, an option agreement was signed with Senju Pharmaceutical covering Japan and Asia. The strategy was pivoted to prioritize Japan development, with ~JPY 200M in equity investment received from Senju Pharmaceutical. The US Phase III trial was deferred
This Quarter Focus:
Concrete clinical trial planning and schedule for Phase III in Japan. Setting of development milestones toward Senju Pharmaceutical's option exercise
Key Metrics:
Clinical trial notification filing timeline, disclosure of R&D cost-sharing framework with Senju Pharmaceutical

4. Bondlido (Post-Herpetic Neuralgia) US Monetization

Prior Quarter:
Approved in the US. Co-developed with Medrx; no P&L contribution in 1Q
This Quarter Focus:
Per the July 14 disclosure, a sales license agreement with Terrain Pharmaceuticals is expected to be signed in August with a 4Q launch. Projected sales volumes are indicated to exceed initial estimates
Key Metrics:
Formal announcement of sales license agreement execution, revenue recognition structure for profit-sharing payments, launch preparation progress

5. Financial Foundation and Cash Runway

Prior Quarter:
Cash and deposits of JPY 1,539M at 1Q-end (−JPY 169M vs. prior fiscal year-end). Quarterly cash burn of ~JPY 170M. Share capital and capital surplus each increased by JPY 24M through stock option exercises. A third-party allotment to Senju Pharmaceutical (~JPY 195M) was executed as a subsequent event
This Quarter Focus:
Cash and deposit levels post Senju Pharmaceutical capital injection. Presence or absence of going concern notes (none in 1Q). Additional fundraising plans
Key Metrics:
Cash and deposits at 2Q-end (our estimate: ~JPY 1,560M post Senju Pharmaceutical injection, ~JPY 1,400M net of 2Q operating cash consumption), equity ratio trend (66.7% at 1Q-end)

Timely Disclosure & Industry Trends

2026/07/14
Updated timeline for Bondlido US sales partnership agreement execution and launch — Sales volume projections exceed initial estimates, prompting a review of contract terms. Agreement execution expected in August, launch in 4Q, crystallizing the monetization timeline. Regarding US Sales Partnership and Launch Timing for "Bondlido"
2026/05/15
Bondlido US sales partnership framework agreement — Agreement on framework terms for sales partnership with Terrain Pharmaceuticals. DWTI will receive performance-based profit-sharing payments, attracting attention as a new revenue source. Notice of Framework Agreement on US Sales Partnership for "Bondlido"
2026/05/14
Completion of payment for new share issuance as restricted stock compensation — 501,200 common shares allocated to directors and employees. Total issuance of JPY 47M with limited dilutive impact, implemented as an ongoing talent retention measure. Notice of Completion of Payment for New Share Issuance as Restricted Stock Compensation

Previous Quarter Results (FY12/2026 1Q Actual)

D. Western Therapeutics Institute is an ophthalmology-focused drug discovery biotech built on a protein kinase inhibitor platform. Its business model combines proprietary drug development with licensing out to major pharmaceutical companies, generating royalty income from marketed products Glaalphar combination ophthalmic solution (glaucoma, licensed to Kowa) and TissueBlue (internal limiting membrane staining, licensed to DORC). In 1Q, revenue came in at −84.4% YoY due to the non-recognition of TissueBlue royalties amid ongoing contract extension negotiations, but SG&A reduction (−20.2%) limited the widening of the operating loss.

Item	Amount	YoY	vs. Guidance	Notes
Revenue	JPY 15M	−84.4%	-	Primarily due to non-recognition of TissueBlue royalties
Operating Income	−JPY 167M	-	-	SG&A reduced −20.2% but revenue decline widened losses
Recurring Profit	−JPY 170M	-	-	Non-operating expenses of JPY 4M (interest expense of JPY 3M, etc.)
Net Income	−JPY 170M	-	-	No extraordinary items
EPS	−JPY 3.14	-	-	Weighted average shares: 54,400K (vs. 43,993K in prior-year period)

Guidance Achievement Rate (Full-Year): Revenue 5.0%, operating loss 21.4% (−JPY 167M / −JPY 780M)

D.Western Therapeutics Institute, Inc.